The role of cytochrome P450 pharmacogenomics in chronic non-cancer pain patients

Tverdohleb T., Dinc B., Knezevic I., Candido K. D., Knezevic N. N.

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, cilt.12, sa.11, ss.1303-1311, 2016 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 12 Sayı: 11
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1080/17425255.2016.1209482
  • Dergi Adı: EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1303-1311
  • Anahtar Kelimeler: Chronic pain, cytochrome P450, CYP2D6, opioids, pharmacogenomics, CYP2D6 GENE DUPLICATION, BREAST-FED NEONATE, HUMAN LIVER, ULTRARAPID-METABOLISM, ALLELE FREQUENCY, ACTIVITY SCORE, GUINEA-PIG, CODEINE, HYDROCODONE, OXYCODONE
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Introduction: Pharmacogenomics is the field that studies an individualized treatment approach for patients' medication regimen that can impact drug safety, productivity, and personalized health care. Pharmacogenomics characterizes the genetic differences in metabolic pathways which can affect a patient's individual responses to drug treatments.